Skip to main content

IOVA Iovance Biotherapeutics, Inc.

Healthcare

quality needs a look, discounted valuation.

Quality
Weak
Valuation
Cheaper
Key signals
52-week adjusted-price high Top-quintile 6-month momentum
10.25
10.25 Close (USD) Loading candles…

Is Iovance Biotherapeutics, Inc. a buy? Fundamentals and valuation first

  • Quality is weaker than peers. Operating margin is only around the 11th percentile. TTM ROE is about -49.0%.

  • Valuation is cheaper than most peers. TTM P/E is in the 16th percentile, lower than most liquid US common stocks.

  • Recent volatility is elevated. 60-day annualized volatility is in the 93th percentile. Average 20-day dollar volume is about $122.2M.

  • Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum currently holds; the tables below show what followed in this stock’s own history.

Watchlist

This page refreshes daily after the close. Add Iovance Biotherapeutics, Inc. to your watchlist to track signal changes on your next visit.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

15 historical occurrences (since 2017-09-19)
Average forward return after 52-week adjusted-price high。20-day: Win 50%, Sample 14, Median -0.61%, Excess +6.16%, Beat mkt rate 50%；60-day: Win 53.8%, Sample 13, Median +1.75%, Excess +7.77%, Beat mkt rate 53.8%；120-day: Win 46.2%, Sample 13, Median -7.27%, Excess +1.71%, Beat mkt rate 46.2%

120 days after: historical avg +11.48%

20-day +6.34%
60-day +10.57%
120-day +11.48%
20-day
60-day
120-day
Win
50%
53.8%
46.2%
Sample
14
13
13
Median
-0.61%
+1.75%
-7.27%
Excess
+6.16%
+7.77%
+1.71%
Beat mkt rate
50%
53.8%
46.2%

Over 13 occurrences, 120-day forward avg gained 11.48%, beat the market by 1.71 pts; win rate 46.2%.

Top-quintile 6-month momentum

Active · now 98.89737065309583%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

21 historical occurrences (since 2016-07-12)
Average forward return after Top-quintile 6-month momentum。20-day: Win 57.1%, Sample 21, Median +2.77%, Excess +10.19%, Beat mkt rate 52.4%；60-day: Win 61.9%, Sample 21, Median +15.2%, Excess +15.88%, Beat mkt rate 57.1%；120-day: Win 55%, Sample 20, Median +7%, Excess +10.13%, Beat mkt rate 50%

120 days after: historical avg +17.28%

20-day +10.2%
60-day +18.2%
120-day +17.28%
20-day
60-day
120-day
Win
57.1%
61.9%
55%
Sample
21
21
20
Median
+2.77%
+15.2%
+7%
Excess
+10.19%
+15.88%
+10.13%
Beat mkt rate
52.4%
57.1%
50%

Over 20 occurrences, 120-day forward avg gained 17.28%, beat the market by 10.13 pts; win rate 55%.

Market-wide momentum baseline

Across 98,576 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.17%, a 57.9% positive-return rate, and +2.82 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

17 times historically; 60-day forward avg +6.96%, win rate 53.3%, beating the market by +2.8 pts on average.

Continue researching Iovance Biotherapeutics, Inc. with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.